Dr.Reddy’s Laboratories (NYSE:RDY) Upgraded by TheStreet to “B-“

TheStreet upgraded shares of Dr.Reddy’s Laboratories (NYSE:RDY) from a c rating to a b- rating in a research note issued to investors on Thursday, TheStreetRatingsTable reports.

RDY has been the topic of several other reports. Macquarie upgraded shares of Dr.Reddy’s Laboratories from a neutral rating to an outperform rating in a research report on Monday, July 1st. Morgan Stanley lowered shares of Dr.Reddy’s Laboratories from an overweight rating to an equal weight rating in a research report on Monday, May 20th. Deutsche Bank assumed coverage on shares of Dr.Reddy’s Laboratories in a research report on Thursday, June 20th. They issued a hold rating on the stock. Zacks Investment Research upgraded shares of Dr.Reddy’s Laboratories from a strong sell rating to a buy rating and set a $40.00 price target on the stock in a research report on Friday, July 19th. Finally, Barclays assumed coverage on shares of Dr.Reddy’s Laboratories in a research report on Tuesday, June 11th. They issued an equal weight rating and a $39.00 price target on the stock. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. Dr.Reddy’s Laboratories has an average rating of Hold and an average price target of $39.50.

NYSE RDY opened at $35.24 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.89 and a quick ratio of 1.32. The firm has a market capitalization of $5.78 billion, a price-to-earnings ratio of 21.49 and a beta of 0.21. The company’s fifty day moving average is $37.24 and its two-hundred day moving average is $38.50. Dr.Reddy’s Laboratories has a 52-week low of $31.58 and a 52-week high of $42.82.

Dr.Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings results on Monday, July 29th. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.18. The company had revenue of $558.00 million for the quarter. Dr.Reddy’s Laboratories had a net margin of 13.44% and a return on equity of 14.94%. As a group, sell-side analysts expect that Dr.Reddy’s Laboratories will post 2.06 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning boosted its position in shares of Dr.Reddy’s Laboratories by 5.1% during the 1st quarter. Creative Planning now owns 6,327 shares of the company’s stock valued at $256,000 after acquiring an additional 305 shares in the last quarter. Signaturefd LLC boosted its position in shares of Dr.Reddy’s Laboratories by 9.4% during the 1st quarter. Signaturefd LLC now owns 3,643 shares of the company’s stock valued at $148,000 after acquiring an additional 312 shares in the last quarter. Greenleaf Trust boosted its position in shares of Dr.Reddy’s Laboratories by 4.0% during the 2nd quarter. Greenleaf Trust now owns 8,512 shares of the company’s stock valued at $319,000 after acquiring an additional 329 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Dr.Reddy’s Laboratories by 0.5% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 86,366 shares of the company’s stock valued at $3,236,000 after acquiring an additional 419 shares in the last quarter. Finally, Private Capital Group LLC boosted its position in shares of Dr.Reddy’s Laboratories by 58.2% during the 1st quarter. Private Capital Group LLC now owns 1,169 shares of the company’s stock valued at $47,000 after acquiring an additional 430 shares in the last quarter. Institutional investors own 12.82% of the company’s stock.

Dr.Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Featured Story: Cost of Goods Sold (COGS)

Analyst Recommendations for Dr.Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.